Thus, treatments using a combination of EGFR inhibitors with surgery or conventional chemotherapy will target both the bulk of the tumor and the cancer stem cell subpopulation, thereby reducing the possibility of relapse and metastasis. This evidence concerns the gene EGFR and neoplasm.